Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Dec;28(12):3733-3737.
doi: 10.1007/s11695-018-3448-9.

Improving Weight Loss by Combination of Two Temporary Antiobesity Treatments

Alfredo Genco  1 , Roberta Ienca  2 , Ilaria Ernesti  2 , Roberta Maselli  3 , Giovanni Casella  1 , Sabrina Bresciani  2 , Stefania Mariani  2 , Emanuele Soricelli  1 , Giovanni Baglio  1 , Michele Lorenzo  4 , Massimo Monti  1
Affiliations
Randomized Controlled Trial

Improving Weight Loss by Combination of Two Temporary Antiobesity Treatments

Alfredo Genco et al. Obes Surg. 2018 Dec.

Abstract

Background: It is generally accepted that the efficacy with an intragastric balloon decreases after the first 4 months of treatment. Aim of this study is to evaluate if the association of a very low-calorie ketogenic diet (VLCKD) can improve the results in terms of weight loss parameters and co-morbidities, as compared to usually prescribed low-calorie diet (LCD).

Methods: For the present study (January 2016-June 2017), 80 patients (20 M/60 F, mean age 37.8 ± 6.1 years; excess weight 56 ± 10 kg; mean BMI 37.2 ± 3.8 kg/m2) underwent Orbera positioning. After 4 months, they were randomized into two groups according to the type of treatment: group A (Bioenterics intragastric balloon - Orbera + VLCKD) (n = 40), and group B (Orbera + LCD) (n = 40).

Results: All patients completed the study with good adherence to diet therapy treatment allocation. After the 6-month treatment period, at time of Orbera removal, mean weight loss was 19 kg and 12 kg in groups A and B respectively (p < 0.05). Mean BMI was 28.9 ± 2.8 and 31.6 ± 3.1 kg/m2 (p < 0.05), and %EWL was 33.1 ± 3.3 and 21.1 ± 2.9 (p < 0.05) in groups A and B respectively. During the last 2 months in group A, the mean weight loss was 8 kg, while in Group B, the main weight loss was 3 kg (p < 0.001). The VLCKD treatment induced a more significant reduction of major comorbidities related to metabolic syndrome.

Conclusions: This study clearly indicates the efficacy of the prescription of very low-calorie ketogenic diet improving the efficacy of intragastric balloon positioning.

Keywords: Intragastric balloon; Ketogenic diet; Weight loss.

PubMed Disclaimer

References

    1. Imaz I, Martinez-Cervell C, Garcia-Alvarez EE, et al. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18:841–6. - DOI
    1. Dumonceau LM. Evidence based review of the bioenterics intragastric balloon for weight loss. Obes Surg. 2008;18:1611–7. - DOI
    1. Genco A, Cipriano M, Bacci V, et al. Bioenterics intragastric balloon (BIB): a short term, double-blind, randomized, controller, crossover study on weight reduction in morbidly obese patients. Int J Obes. 2006;30:129–33. - DOI
    1. Lorenzo M, Genco A, Intragastric balloon for the treatment of morbid obesity. In (Preedy VR, Rajendram R. Intragastric Balloon for the Treatment of Morbid Obesity. In: Martin CR, editor. Metabolism and pathophysiology of bariatric surgery. London: Academic Press; 2017. p. 139–46. - DOI
    1. Alfalah H, Philippe B, Ghazal F, et al. Intragastric balloon for preoperative weight reduction in candidates for laparoscopic gastric bypass with massive obesity. Obes Surg. 2006;16:147–50. - DOI

Publication types

LinkOut - more resources